About Shine Pharmaceuticals Limited
Data last updated: 18 December 2025
Shine Pharmaceuticals Limited is a public limited company based in Vadodara, Gujarat, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 17 August 1994, the company has been in operation for over 32 years.
Registered with ROC Ahmedabad under CIN U24231GJ1994PTC022787.
Capital: an authorised share capital of ₹5 Cr and a paid-up capital of ₹3.38 Cr. Formerly known as Shine Pharmaceuticals Private Limited. It is led by directors including Tejal Ashish Parikh and Hiranmay Saha.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: Vadodara, Gujarat.
As per the financials filed for FY 2025, the company reported a revenue of ₹120.09 Cr, a decline of 4% compared to the previous year.
The company has a workforce of approximately 780 employees as per the latest available data.
The company is associated with 1 brand - Shine Pharmaceuticals. As per MCA filings, the company has open charges of ₹6.8 Lakh and satisfied charges of ₹9.3 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website shinepharma.com.
-
Email**************
-
Telephone**************
-
Website**************
-
Social Media
-
Registered Address309 – 310 Dwarkesh Complex 3Rd Floor Sun Pharma Road Off. Old Padra Road At, Ladara, Vadodara, Gujarat, India – 390012
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Shine Pharmaceuticals Limited
Shine Pharmaceuticals Limited has one previous CIN (Corporate Identification Number): U24231GJ1994PTC022787. The current CIN is U24231GJ1994PLC022787, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24231GJ1994PLC022787 | Current |
| U24231GJ1994PTC022787 | Previous |
Associated Brands with Shine Pharmaceuticals Limited
Shine Pharmaceuticals Limited operates one associated brand: Shine Pharmaceuticals. These brands represent Shine Pharmaceuticals Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Specialty pharmaceutical company producing formulations for psychiatry, cardiology, and gastroenterology. | shinepharma.com |
Competitors & Alternatives of Shine Pharmaceuticals Limited
Brands and companies operating in the same space as Shine Pharmaceuticals Limited include Merck, Roivant Sciences, AbbVie and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Merck
|
Pharmaceutical products are manufactured and marketed worldwide. | Kenilworth, United Kingdom, United Kingdom | 1891 |
Roivant Sciences
|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | New York, United States, United States | 2014 |
AbbVie
|
Biopharmaceutical research and drug development are conducted globally by AbbVie. | Chicago, United States, United States | 2012 |
Lilly
|
Traditional pharmaceutical medicines are developed for multiple health fields. | United States | 1876 |
Gilead
|
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | Foster City, United States, United States | 1987 |
United Therapeutics
|
Treatments for chronic and life-threatening diseases are developed and commercialized. | Silver Spring, United States, United States | 1998 |
Roche
|
Pharmaceuticals and diagnostics kits are developed for various diseases. | Basel, Switzerland, Switzerland | 1896 |
Ascendis Pharma
|
Long-acting prodrug therapies are developed for endocrine and rare diseases. | Hellerup, Denmark, Denmark | 2007 |
MorphoSys
|
Therapeutic antibodies for cancer and other diseases are developed. | Planegg, Germany, Germany | 1992 |
Vertex Pharmaceuticals
|
Developer of drugs for the treatment of multiple disorders | United States | 1989 |
Business Activity of Shine Pharmaceuticals Limited
Shine Pharmaceuticals Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Board of Directors of Shine Pharmaceuticals Limited
Shine Pharmaceuticals Limited is currently managed by 6 directors, with 5 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Tejal Ashish Parikh
Also directs:
Mew Electricals Limited
|
Director | 30 Mar 2024 | 2 Years 3 Months | Current |
| Hiranmay Saha | Director | 30 May 1996 | 30 Years 1 Months | Current |
| Samir Chakraborty | Managing Director | 01 Apr 2005 | 21 Years 3 Months | Current |
|
Rangoli Saurav Gada
Also directs:
Link Pharmachem Limited, Medicap Healthcare Limited
|
Director | 25 Mar 2023 | 3 Years 3 Months | Current |
| Aloka Saha | Whole-Time Director | 30 May 1996 | 30 Years 1 Months | Current |
|
Pradeep Vishambhar Agrawal
Also directs:
Bharat Petroleum Corporation Limited, Vital Care Pvt Ltd, Interpharm Biotech Private Limited and 4 more
|
Whole-Time Director | 01 Jul 2003 | 23 Years 0 Months | Current |
Financials of Shine Pharmaceuticals Limited FY 2025 filings available
Shine Pharmaceuticals Limited reported revenue of ₹120.09 Cr (down 4% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Charges & Borrowings of Shine Pharmaceuticals Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Jun 2019 | Axis Bank Limited | ₹6.8 Lakh | Open |
| 24 Dec 2020 | Others | ₹2 Cr | Satisfied |
| 26 Sep 2019 | Others | ₹75 Lakh | Satisfied |
| 03 Jan 2004 | Bank of Baroda | ₹3.55 Cr | Satisfied |
| 05 Jul 2003 | Bank of Baroda | ₹3 Cr | Satisfied |
Total charge records: 5 View all charges
Employees and EPFO Compliance at Shine Pharmaceuticals Limited
View historical data on people associated with Shine Pharmaceuticals Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Shine Pharmaceuticals Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Shine Pharmaceuticals Limited
GSTIN & GST Filing Data of Shine Pharmaceuticals Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Shine Pharmaceuticals Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Shine Pharmaceuticals Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Shine Pharmaceuticals Limited
MSME Payment Delays by Shine Pharmaceuticals Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Shine Pharmaceuticals Limited
Subsidiaries & Group Companies of Shine Pharmaceuticals Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Shine Pharmaceuticals Limited with ownership details.
MCA Filings & Documents of Shine Pharmaceuticals Limited
MCA Filings & Documents of Shine Pharmaceuticals Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Shine Pharmaceuticals Limited
Frequently Asked Questions about Shine Pharmaceuticals Limited
Shine Pharmaceuticals Limited is an active public limited company in the pharma sector based in Vadodara, Gujarat, India. It was incorporated on 17 August 1994 (32+ years old) and is registered under CIN U24231GJ1994PLC022787. The company has 780 employees.
Shine Pharmaceuticals Limited reported revenue of ₹120.09 Cr for FY 2025 (down 4.00% YoY).
The current directors of Shine Pharmaceuticals Limited are:
The primary industry of Shine Pharmaceuticals Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Shine Pharmaceuticals Limited can be reached at the registered office: 309 – 310 Dwarkesh Complex 3Rd Floor Sun Pharma Road Off. Old Padra Road At, Ladara, Vadodara, Gujarat, India – 390012, or through the website shinepharma.com.
The authorised capital is ₹5 Cr, and the paid-up capital is ₹3.38 Cr.